News

Alirocumab is an investigational monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Under the Prescription Drug User Fee Act (PDUFA), the goal for a priority review is

Prestalia is the first fixed-dose combination of perindopril arginine and amlodipine, may be used in patients whose blood pressure is not adequately controlled on monotherapy. The drug may

Assistant professor of biochemistry and molecular biology at Saint Louis University Mee-Ngan F. Yap, Ph.D studied staph that had been treated with the antibiotic azithromycin. During the study

If approved in the EU, ruxolitinib could provide the first targeted treatment option for these patients. PV is a chronic, incurable blood cancer associated with an overproduction of

Lupuzor (also called as Rigerimod, IPP-201101 and P140) received fast track designation from the US Food and Drug Administration (FDA) as well as approval to start Phase III

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH. Natpara, a bioengineered replica of human PTH, is expected to be available in

The Fast Track designation process of the FDA is designed to facilitate the development and expedite the review and approval of drugs intended to treat serious or life

"Retinal vein occlusion is a common retinal vascular disorder with an estimated 16.4 million people affected worldwide, and it is a severe disease which is potentially blinding if

The in-clinic, randomized, placebo-controlled, double-blind Phase IIa trial will evaluate patients with epilepsy using the intermittent photo-stimulation model. The trial’s primary aim is to evaluate the safety and